Adaptive Biotechnologies shares fall 4.03% intraday after terminating strategic collaboration with Genentech.

Adaptive Biotechnologies Corporation dropped 4.03% in intraday trading, following the announcement that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. The termination of the agreement, which was entered in 2018 to collaborate on research and development of certain cancer cell therapy products, is expected to release Adaptive from exclusivity obligations regarding cell therapies in oncology.